Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
Thursday, August 18, 2022
Aytu BioPharma, Inc., a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,273,148 (the "'148 patent"), for AR101/Enzastaurin. This patent, titled "Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition," covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome. This is the first issued patent supporting the portfolio and has an expiry date in August of 2038, assuming no patent term extensions.
"This first patent issuance supporting the portfolio is an important milestone as we build out a broad, global suite of intellectual property supporting AR101. This is the first of multiple patent families filed which are collectively aimed at yielding both IP breadth and depth to our global patent suite," remarked Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023."
